SynAct Pharma AB
17.40
SEK
-0.04
(-0.23%)
SynAct Pharma AB
STO:SYNACT
(Nasdaq Stockholm)
Recent
price
17.40
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
SEK
•
in mil. unless spec.Working Capital
SEK
•
in mil. unless spec.Growth Rates
SEK
•
in mil. unless spec.Quarterly Revenue
SEK
•
in mil. unless spec.Quarterly Earnings Per Share
SEK
•
in mil. unless spec.Quarterly Dividends Per Share
SEK
•
in mil. unless spec.- Similar Companies
- Business
- SynAct Pharma AB is a clinical-stage biotechnology company headquartered in Lund, Sweden, specializing in the research and development of innovative medicines for inflammatory and autoimmune diseases. The company develops selective melanocortin receptor agonists designed to stimulate and resolve inflammation by activating the body's own immune regulatory system. Its core product portfolio includes AP1189 (resomelagon), an oral selective melanocortin agonist in Phase 2 clinical trials targeting the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. Additionally, SynAct develops TXP-11, an advanced peptide agonist in preclinical trials aimed at preventing organ failure during surgery, along with other drug programs focused on autoimmune and inflammatory diseases. Founded in 2012, SynAct Pharma operates primarily in Sweden and has expanded its reach through the acquisition of TXP Pharma AG, a Swiss biotechnology company, completed in late 2022. This acquisition strategically broadened SynAct's pipeline and enhanced its peptide drug development capabilities. Recently, SynAct has initiated a Phase 2b clinical study for AP1189 in treatment-naïve rheumatoid arthritis patients and commenced a Phase 2 trial for dengue treatment, following FDA approval for an Investigational New Drug (IND) application. The company also secured U.S. patents for AP1189 combination therapies, reflecting its advancing intellectual property position. To strengthen its financial position and support ongoing development efforts, SynAct Pharma secured a SEK 30 million credit facility extending its operational runway to mid-2026 and completed a directed share issue raising SEK 37 million. These financial moves enable continued advancement of its lead compounds and exploration of partnership opportunities. SynAct remains focused on harnessing selective melanocortin activation to develop novel treatments that provide immune balance and effective resolution of inflammation across multiple indications, maintaining operations out of its Lund headquarters and with subsidiaries including TXP Pharma in Switzerland.